Science News
from research organizations

Gene Test Determines Risk Of Heart Surgery Complications

Date:
May 7, 2009
Source:
Helmholtz Association of German Research Centres
Summary:
Genetic differences can explain why some patients undergoing heart surgery later experience shock and kidney complications, according to a new study. The results indicate that performing a genetic test on patients before they have surgery can help guide treatment after they leave the operating room.
Share:
         
Total shares:  
FULL STORY

Genetic differences can explain why some patients undergoing heart surgery later experience shock and kidney complications, according to a study by researchers at the Charité – Universitätsmedizin Berlin, the Max-Delbrück-Center for Molecular Medicine (MDC) Berlin-Buch in Germany and the Austin Hospital in Melbourne, Australia. The results indicate that performing a genetic test on patients before they have surgery can help guide treatment after they leave the operating room.

The researchers studied the gene that encodes the enzyme catechol-O-methyltransferase (COMT). Certain variants of the COMT gene have long been suspected to play a role in shock and kidney failure in patients following heart surgery. The COMT enzyme is involved in metabolizing norepinephrine (noradrenalin), a drug that is given to patients post-surgery to stimulate their blood flow and to normalize their blood pressure.

Professor Duska Dragun, MD, Charité, Professor Friedrich Luft, MD (Experimental and Clinical Research Center , MDC) and Dr. Wolf-Hagen Schunck (MDC) studied the COMT gene in 260 patients who underwent heart bypass surgery. They were able to show that the genetic variant they call "LL" can lower the activity of the COMT enzyme. As a result, LL patients are more likely to develop shock and kidney failure.

In addition, LL patients who experience shock do not respond very well to treatment with norepinephrine. Since the activity of the COMT enzyme is lowered in LL patients, norepinephrine cannot fully be metabolized. As a result, too much norepinephrine remains in the body and the drug is no longer effective.

Therefore, the researchers suggest that "perhaps, more suitable hemodynamics could be achieved in LL patients were they given vasopressin rather than noradrenaline (norepinephrine) and acute kidney injury might be attenuated by avoidance of cardiopulmonary bypass and nephrotoxic medication." Larger clinical trials are necessary to show whether patients need to undergo genetic testing prior to heart surgery to determine their risk for shock and kidney failure.


Story Source:

The above story is based on materials provided by Helmholtz Association of German Research Centres. Note: Materials may be edited for content and length.


Journal Reference:

  1. Anja Haase-Fielitz et al. Decreased Catecholamine Degradation Associates with Shock and Kidney Injury after Cardiac Surgery. Journal of the American Society of Nephrology, DOI: 10.1681/ASN.2008080915

Cite This Page:

Helmholtz Association of German Research Centres. "Gene Test Determines Risk Of Heart Surgery Complications." ScienceDaily. ScienceDaily, 7 May 2009. <www.sciencedaily.com/releases/2009/04/090430172944.htm>.
Helmholtz Association of German Research Centres. (2009, May 7). Gene Test Determines Risk Of Heart Surgery Complications. ScienceDaily. Retrieved April 26, 2015 from www.sciencedaily.com/releases/2009/04/090430172944.htm
Helmholtz Association of German Research Centres. "Gene Test Determines Risk Of Heart Surgery Complications." ScienceDaily. www.sciencedaily.com/releases/2009/04/090430172944.htm (accessed April 26, 2015).

Share This Page:


Health & Medicine News
April 26, 2015

Latest Headlines
updated 12:56 pm ET